Current progress in anticalcification for bioprosthetic and polymeric heart valves

Cardiovascular Pathology

Volumn 6, Issue 4, 1997, Pages 219-229

  Vyavahare, Narendra R ^a   Chen, Weiliam ^a   Joshi, Ravi R ^a   Lee, Chi Hyun ^a   Hirsch, Danielle ^b   Levy, Judith ^d   Schoen, Frederick J ^c   Levy, Robert J ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d EASTERN MICHIGAN UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYURETHAN;

ARTICLE; CALCIFICATION; HEART VALVE PROSTHESIS; HUMAN; PRIORITY JOURNAL;

EID: 0030906831     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(97)00017-3     Document Type: Article

References (112)

1. Milano A, Bortolotti U, Talenti E, et al. Calcific degeneration as the main cause of porcine bioprosthetic valve failure. Am J Cardiol 1984;53:1066-1070.
2. Schoen FJ, Levy RJ, Piehler HR. Pathological considerations in replacement cardiac valves. Cardiovasc Pathol 1992;1:29-52.
3. Grunkemeier GL, Jamieson WRE, Miller DC, Starr A. Actuarial versus actual risk of porcine structural valve deterioration. J Thorac Cardiovasc Surg 1994;108:709-718.
4. Golomb G, Schoen FJ, Smith MS, Linden J, Dixon M, Levy RJ. The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol 1987; 127:122-130.
5. Schoen FJ, Levy RJ, Nelson AC, Bernhard WF, Nashef A, Hawley M. Onset and progression of experimental bioprosthetic heart valve calcification. Lab Invest 1985;52:523-532.
6. Schoen FJ, Tsao JW, Levy RJ. Calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol 1985;123:134-145.
7. Levy R, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 1983;113:143-155.
8. 3 preincubations. J Biomed Mater Res 1991;25:905-935.
9. Schoen FJ, Levy RJ. Heart valve bioprostheses: antimineralization. Eur J Cardiothorac Surg 1992;5(Suppl 1):S91-S94.
10. Levy RJ, Schoen FJ, Howard SL. Mechanism of calcification of porcine bioprosthetic aortic valve cusps: Role of T-lymphocytes. Am J Cardiol 1983;52:629-631.
11. Jones M, Eidbo EE, Hilbert SL, Ferrans VJ, Clark RE. Anticalcification treatments of bioprosthetic heart valves: in vivo studies in sheep. J Card Surg 1989;4:69-73.
12. Fishbein MC, Levy RJ, Ferrans VJ, et al. Calcification of cardiac valve bioprostheses. Biochemical, histologic, and ultrastructural observations in a subcutaneous implantation model system. J Thorac Cardiovasc Surg 1982;83:602-609.
13. Barnhart GR, Jones M, Ishihara T, Chavez AM, Rose DM, Ferrans VJ. Failure of porcine aortic and bovine pericardial prosthetic heart valves: An experimental investigation in young sheep. Circulation 1982:I150-153.
14. Schoen FJ, Hirsch D, Bianco RW, Levy RJ. Onset and progression of calcification in porcine aortic bioprosthetic valves implanted as orthotopic mitral valve replacements in juvenile sheep. J Thorac Cardiovasc Surg 1994;108:880-887.
15. Schoen FJ, Kujovich JL, Webb CL, Levy RJ. Chemically determined mineral content of explanted porcine aortic valve bioprostheses: correlation with radiographic assessment of calcification and clinical data. Circulation 1987;76:1061-1066.
16. Schoen FJ, Golomb G, Levy RJ. Calcification of bioprosthetic heart valves: A perspective on models. J Heart Valve Dis 1992;1:110-114.
17. Schoen FJ, Levy RJ, Hilbert SL, Bianco RW. Antimineralization treatments for bioprosthetic heart valves: Assessment of efficacy and safety. J Thorac Cardiovasc Surg 1992;104:1285-1288.
18. Fleisch H. Bisphosphonates: Mechanisms of action and clinical use. In: Mundy GR, Martin TJ, eds. Physiology and Pharmacology of Bone. New York: Springer-Verlag, 1993:377-418.
19. Hirsch D, Schoen FJ, Levy RJ. Effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity. Biomaterials 1992; 14: 371-377.
20. Levy RJ, Hawley MA, Schoen FJ, Lund SA, Liu PU. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats. Circulation 1985; 71:349-356.
21. Levy RJ, Wolfrum J, Schoen FJ, Hawley MA. Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 1985;228:190-192.
22. Webb CL, Benedict JJ, Schoen FJ, Linden JA, Levy RJ. Inhibition of bioprosthetic heart valve calcification with amino diphosphonate covalently bound to residual aldehyde groups. Ann Thorac Surg 1988;46:309-316.
23. Levy RJ, Schoen FJ, Lund SA, Smith MS. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. J Thorac Cardiovasc Surg 1987;94:551-557.
24. Golomb G, Langer R, Schoen FJ, Smith MS, Choi YM, Levy RJ. Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. J Controlled Release 1986;4:181-194.
25. Golomb G, Dixon M, Smith MW, Schoen FJ, Levy RJ. Inhibition of bioprosthetic heart valve calcification by sustained local delivery of Ca and Na diphosphonate via controlled release matrices. Trans Am Soc Artif Intern Organs 1986;XXXII:587-590.
26. Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ. Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: Release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 1987;76:271-276.
27. Golomb G, Levi M, Van G, Joel M. Controlled release of bisphosphonate from a biodegradable implant: Evaluation of release kinetics and anticalcification effect. J Appl Biomat 1992;3:23-28.
28. 3 and ethanehydroxydiphosphonate: Preincubation and polymeric controlled release studies. Biomaterials 1993;14:705-711.
29. Johnston TP, Bove EL, Bolling SF, et al. Controlled release of 1-hydroxyethylidene disphosphonate: In vitro assessment and effects on bioprosthetic calcification in sheep tricuspid valve replacements. Int J Pharm 1989;52:139-148.
30. Johnston TP, Boyd JA, Ciesliga BL, Schoen FJ, Amidon G, Levy RJ. Controlled release of ethanehydroxy diphosphonate from polyurethane reservoirs to inhibit calcification of bovine pericardium used in bioprosthetic heart valves. Int J Pharm 1990;59:95-104.
31. Levy RJ, Golomb G, Wolfrum J, Lund SA, Schoen FJ, Langer R. Local controlled-release of diphosphonates from ethylenevinylacetate matrices prevents bioprosthetic heart valve calcification. ASAIO Trans 1985;XXXI:459-463.
32. Levy RJ, Johnston TP, Sintov A, Golomb G. Controlled release implants for cardiovascular disease. J Controlled Release 1990;11:245-254.
33. 3: controlled release polymers for preventing calcification of bioprosthetic aortic wall. J Controlled Release 1995;34:97-108.
34. Levy RJ, Labhasetwar V, Song C, et al. Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. J Controlled Release 1995;36:137-147.
35. David TE, Bos J, Rakowski H. Aortic valve replacement with the Toronto SPV bioprosthesis. J Heart Valve Dis 1992;1:244-248.
36. Chen W, Schoen FJ, Levy RJ. Mechanism of efficacy of 2-amino oleic acid for inhibition of calcification of glutaraldehyde-pretreated porcine bioprosthetic heart valves. Circulation 1994;90:323-329.
37. Biedrzycki LM, Lerner E, Levy RJ, Schoen FJ. Differential calcification of cusps and aortic wall of failed stented porcine bioprosthetic valves. J Biomed Mater Res 1997;34:411-415.
38. Girardot MN, Torrianni M, Girardot JMD. Effect of AOA on glutaraldehyde-fixed bioprosthetic heart valve cusps and walls: binding and calcification studies. Int J Artific Organs 1994;17:76-82.
39. Levy RJ, Qu X, Underwood T, Trachy J, Schoen FJ. Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. J Biomed Mater Res 1995;29:217-226.
40. 3+ preincubation inhibits calcification of bioprosthetic heart valve tissue in the rat subdermal model. ASAIO Trans 1988;34:855-859.
41. 3+ preincubation inhibits calcification of aortic homografts in the rat subdermal model. ASAIO Trans 1988;34:851-854.
42. 3+ for prevention of bioprosthetic heart valve calcification. ASAIO Trans 1990;36:M408-410.
43. 3. Am J Pathol 1991;138:971-981.
44. 3+, protamine sulphate and levamisole. Biomaterials 1990;11:718-723.
45. Chen W, Kim JD, Schoen FJ, Levy RJ. Effects of 2-amino oleic acid exposure conditions on the inhibition of calcification of glutaraldehyde cross-linked porcine aortic valves. J Biomed Mater Res 1995; 28:1485-1495.
46. Gott JP, Pan-Chih, Dorsey LMA, et al. Calcification of porcine valves: a successful new method of antimineralization. Ann Thorac Surg 1992;53:207-216.
47. 3 and 2-amino oleic acid. J Appl Biomater 1997;38:43-48.
48. Jones M, Eidbo EE, Hilbert SL, Ferrans VJ, Clark RE. The effects of anticalcification treatments on bioprosthetic heart valves implanted in sheep. ASAIO Trans 1988;34:1027-1030.
49. Hirsch D, Drader J, Thomas T, Schoen FJ, Levy JT, Levy RJ. Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: preincubation and controlled release studies. J Biomed Mater Res 1993;27:1477-1484.
50. Wilson GJ, Yeger H, Klement P, Lee JM, Courtman DW. Acellular matrix allograft small caliber vascular prostheses. Trans Am Soc Artif Intern Organs 1990;36:M340-M343.
51. Courtman DW, Pereira CA, Kashef V, McComb D, Lee JM, Wilson GJ. Development of a pericardial acellular matrix biomaterial: Biochemical and mechanical effects of cell extraction. J Biomed Mater Res 1994;28:655-666.
52. Courtman DW, Pereira CA, Omar S, Langdon SE, Lee JM, Wilson GJ. Biomechanical and ultrastructural comparison of cryopreservation and a novel cellular extraction of porcine aortic valve leaflets. J Biomed Mater Res 1995;29:1507-1516.
53. Vesely I, Noseworthy R, Pringle G. The hybrid xenograft/autograft bioprosthetic heart valve: in vivo evaluation of tissue extraction. Ann Thorac Surg 1995;60:S359-S364.
54. Wilson GJ, Courtman DW, Klement P, Lee JM, Yeger H. Acellular matrix: a biomaterials approach for coronary artery bypass and heart valve replacement. Ann Thorac Surg 1995;60(Suppl 2):S353-S358.
55. Huang-Lee LL, Cheung DT, Nimni ME. Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. J Biomed Mater Res 1990;24:1185-1201.
56. Grabenwoger M, Grimm M, Eybl E, et al. Decreased tissue reaction to bioprosthetic heart valve material after L-glutamic acid treatment. A morphological study. J Biomed Mater Res 1992;26:1231-1240.
57. Bernacca GM, Dimitri WR, Fisher AC, Mackay TG, Wheatley DJ. Chemical modification of bovine pericardium and its effect on calcification in the rat subdermal model. Biomaterials 1992;13:345-352.
58. Imamura E, Sawatani O, Koyanagi H, Noishiki Y, Miyata T. Epoxy compounds as a new cross-linking agent for porcine aortic leaflets: subcutaneous implant studies in rats. J Card Surg 1989;4:50-57.
59. Xi T, Ma J, Tian W, Lei X, Long S, Xi B. Prevention of tissue calcification on bioprosthetic heart valve by using epoxy compounds: a study of calcification tests in vitro and in vivo. J Biomed Mater Res 1992;26:1241-1251.
60. Sung HW, Shen SH, Tu R, et al. Comparison of the cross-linking characteristics of porcine heart valves fixed with glutaraldehyde or epoxy compounds. ASAIO J 1993;39:M532-M536.
61. Noishiki Y, Takahashi K, Yamamoto K, Matsumoto A, Yamane Y, Miyata T. A new cardiac wall substitute with high affinity for fibroblasts that can induce an endothelial cell lining. ASAIO J 1994; 40:M751-M756.
62. Tang Z, Yue Y. Crosslinkage of collagen by polyglycidyl ethers. ASAIO J 1995;41:72-78.
63. Myers DJ, Nakaya G, Girardot MN, Christie GW. A comparison between glutaraldehyde and diepoxide-fixed stentless porcine aortic valves: Biochemical and mechanical characterization and resistance to mineralization. J Heart Valve Dis 1995;4(Suppl 1):S98-S101.
64. Lee JM, Pereira CA, Kan LW. Effect of molecular structure of poly(glycidyl ether) reagents on crosslinking and mechanical properties of bovine pericardial xenograft material. J Biomed Mater Res 1994;28:981-992.
65. Moore MA, Bohachevsky IK, Cheung DT, et al. Stabilization of pericardial tissue by dye-mediated photooxidation. J Biomed Mater Res 1994;28:611-618.
66. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993;143:1003-1008.
67. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-1696.
68. Bostrom K, Watson KE, Horn S, Wortham C, Herman JM, Demer LL. Bone morphogenic protein expression in human atherosclerotic lesions. J Clin Invest 1993;91:1800-1809.
69. Levy RJ, Gundberg C, Scheinman C. The identification of the vitamin K-dependent bone protein osteocalcin as one of the gamma-carboxy-glutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983;46:49-56.
70. Shanahan CM, Cary NRB, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994;93:2393-2402.
71. Maranto AR, Schoen FJ. Alkaline phosphatase activity of glutaralde-hyde-treated bovine pericardium used in bioprosthetic cardiac valves. Circ Res 1988;63:844-848.
72. Hsu HHT, Anderson HC. A role for ATPase in the mechanisms of ATP-dependent Ca and phosphate deposition by isolated rachitic matrix vesicles. Int J Biochem 1995;27:1349-1356.
73. Boskey AL. Noncollagenous matrix proteins and their role in mineralization. Bone and Mineral 1989;6:111-123.
74. Veis A. Phosphophoryns of dentin and bone. Do they have a role in matrix mineralization? In: Butler WT, ed. The Chemistry and Biology of Mineralized Connective Tissues. Birmingham, AL: Ebsco, 1985:170.
75. Termine JD, Kleinman HD, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone specific protein binding mineral to collagen. Cell 1981;26:99-105.
76. Romberg RW, Werness PG, Lollar BL, Riggs BL, Mann KG. Isolation and characterization of native adult osteonectin. J Biol Chem 1985;260:2728-2736.
77. Lane TF, Iruela-Arispe ML, Sage EH. Regulation of gene expression by SPARC during angiogenesis in vitro. J Biol Chem 1992;88: 16736-16745.
78. ++-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:2648-2652.
79. Kinne RW, Fisher LW. Keratin sulfate proteoglycan in rabbit compact bone is sialoprotein II. J Biol Chem 1987;262:10206-10211.
80. Frenzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985;232: 715-724.
81. Butler WT. The nature and significance of osteopontin. J Biol Chem 1989;267:1-7.
82. Reinholt FP, Hultenby K, Oldberg A, Heingard D. Osteopontin, a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990;87:4473-4475.
83. Oldberg A, Franzen A, Heinegard D. The primary structure of a cell-binding bone sialoprotein. J Biol Chem 1988;263:19430-19432.
84. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression of bone sialoprotein in developing human tissues. Calcif Tiss Inter 1991;49:421-426.
85. Gorski JP, Griffith D, Dudley G, et al. Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phases of bone and growth plate and in serum. J Biol Chem 1990;265:14956-14963.
86. Gorski JP, Shimuzi K. Isolation of new phosphorylated glycoprotein from mineralized phase of bone that exhibits limited homology to adhesive protein osteopontin. J Biol Chem 1988;263:15938-15945.
87. Chen Y, Bal BS, Gorski JP. Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 1992;267:24871-24878.
88. Price PA. Role of vitamin K-dependent proteins in bone metabolism. Ann Rev Nutr 1988;8:865-883.
89. Cheung DT, Perelman N, Ko EC, Nimni ME. Mechanism of cross-linking of proteins by glutaraldehyde III. Reaction with collagen in tissues. Conn Tissue Res 1985;13:109-115.
90. Levy RJ, Zenker JA, Lian JB. Vitamin K-dependent calcium binding proteins in aortic valve calcification. J Clin Invest 1980;65:563-566.
91. Gura TA, Wright KL, Veis A, Webb CL. Identification of specific mineral binding non-collagenous proteins associated with glutaraldehyde preserved bovine pericardium in the rat subdermal model. J Biomed Mater Res (in press).
92. Sanders SP, Levy RJ, Freed MD, Norwood WI, Castaneda AR. Use of Hancock porcine xenografts in children and adolescents. Am J Cardiol 1980;46:429-438.
93. Boskey AL, Meresca M, Ullrich W, Doty SB, Butler WT, Prince CW. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone and Mineral 1993;22:147-159.
94. Aktsu T, Dreyer B, Kolff WJ. Polyurethane artificial heart valves in animals. J Appl Physiol 1985;14:1045-1048.
95. Yu LS, Yuan B, Bishop D, et al. New polyurethane valves in new soft artificial hearts. ASAIO Trans 1989;35:301-304.
96. Fishbein MC, Roberts WC, Golden A, Hufnagel CA. Cardiac pathology after aortic valve replacement using Hufnagel trileaflet protheses: a study of 20 necropsy patients. Am Heart J 1975;89:443-448.
97. Lelah MD, Cooper SL. Polyurethanes in Medicine. Boca Raton, FL: CRC Press, 1986:22-34.
98. Wisman CB, Pierce WS, Donachy JH, Pae WE, Myers JL, Prophet GA. A polyurethane trileaflet cardiac valve prosthesis: in vitro and in vivo studies. Trans Am Soc Artif Intern Organs 1982;28:164-168.
99. Whalen RL, Snow JL, Haraski H, Nose Y. Mechanical strain and calcification in blood pumps. Trans Am Artif Intern Organs 1980;24: 487-491.
100. Hilbert SL, Ferrans VJ, Tomita Y, Eidbo EE, Jones M. Evaluation of explanted polyurethane trileaflet cardiac valve prostheses. J Thorac Cardiovasc Surg 1987;94:419-429.
101. Szycher M. High performance biomaterials: A comprehensive guide to medical and pharmaceutical applications. Lancaster, PA: Technomic Publishing, 1991:37-71.
102. Joshi RR, Frautschi JR, Phillips RE, Jr., Levy RJ. Phosphonated polyurethanes that resist calcification. J Appl Biomater 1994;5:65-77.
103. Joshi RR, Frautschi JR, Phillips RE, Jr., Levy RJ. Immobilized heparin and heparin-bisphosphonate prevent polyurethane calcification and thrombosis: in vitro and in vivo studies. Fifth World Biomaterials Congress, Toronto, Canada, May 29-June 2, 1996.
104. Joshi RR, Levy RJ. Calcification resistant synthetic biomaterials. U.S. Patent. USA 1995;5:435-790.
105. Joshi RR, Underwood T, Frautschi JR, Phillips RE, Jr., Levy RJ. Calciphylaxis-enhanced calcification of polyurethanes implanted subdermally in rats. J Biomed Mater Res 1996;31:201-207.
106. Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 1995;60:S513-S516.
107. Stevenson DM, Yoganathan AP, Williams FP. Numerical simulation of steady turbulent flow through trileaflet aortic heart valves - II. Results on five models. J Biomech 1985;18(12):909-926.
108. Clark RE, Hagen RW, Siegfried BA, Schier JJ, Rusche JM. Accelerated fatigue testing of prosthetic heart valves. Surg Forum 1975;26: 242-243.
109. Idelsohn SR, Coasta LE, Ponso R. A comparative computational study of blood flow through prosthetic heart valves using the finite element method. J Biomech 1985;18(2):97-115.
110. Hilbert SL, Barrick MK, Ferrans VJ. Porcine aortic valve bioprostheses: a morphologic comparison of the effects of fixation pressure. J Biomed Mater Res 1990;24:773-787.
111. Flomenbaum MA, Schoen FJ. Effects of fixation back pressure and antimineralization treatment on the morphology of porcine aortic bioprosthetic valves. J Thorac Cardiovasc Surg 1993;105(1):154-164.
112. Nelson AC, Schoen FJ, Levy RJ. Scanning electron microscopy methodology for study of the pathophysiology of calcification in bioprosthetic heart valves. Scanning Electron Microscopy 1985;I:209-213.